Anti-epilepsy drug topiramate triples the risk of birth defects like cleft palate, the FDA warns - latimes.com
Links shared publicly online about this topic.
The anti-epilepsy drug topiramate triples the risk of cleft palate and other birth defects of the oral cavity when taken during the first trimester of pregnancy compared with other anti-epilepsy drugs, the Food and Drug Administration warned Friday. In addition to being used to control epileptic seizures, the drug, sold under the brand name Topamax, is FDA-approved for preventing migraine headaches and is used off-label for some other purposes, including appetite control. For those uses, the ris View full resource at latimes.com
Tags: Migraine Prevention Medication, Seizure Medication, Drug, Childbirth, FDA, Topamax, Epilepsy Medication
Most Recently Shared on March 4, 2011 at 11:40 pm By: